Early-Stage Lung Cancer Diagnostics Market

Introduction

Apoptosis is a form of programmed cell death or cellular suicide. Apoptosis-susceptible cells are used in early-stage lung cancer diagnostics for the treatment of cytotoxic cancer. The agents of early-stage lung cancer diagnostics interact with the targeted cell to induce cell death. Early-stage lung cancer diagnostics has the ability to engage with the cancer cell.

Early-stage lung cancer diagnostics works on the coupling phenomenon of drug-target interaction. The drug-target phenomenon of early-stage lung cancer diagnostics is the key factor behind the accuracy of the treatment. A few patients may show dramatic side-effects after undergoing cancer treatment with early-stage lung cancer diagnostics.

Early-Stage Lung Cancer Diagnostics Market: Drivers and Restraints

The rising prevalence of leukemia and prostate cancer is the primary factor driving the growth of the early-stage lung cancer diagnostics market. Increasing funding by governments for the development of novel therapies for the treatment of cancer is expected to boost the early-stage lung cancer diagnostics market over the forecast period even more.

Additionally, the rising focus of pharmaceutical companies on launching improved drugs for the treatment of cancer is also expected to fuel the growth of the early-stage lung cancer diagnostics over the next decade. Also, a surge in the treatment adoption in developing countries is anticipated to boost the revenue of the early-stage lung cancer diagnostics market.

On the other hand, the high cost of drugs may hamper the growth of the early-stage lung cancer diagnostics market to some extent. Moreover, the lack of awareness about the advanced therapies for cancer treatment among people is also expected to deter the growth of the early-stage lung cancer diagnostics market over the forecast period.

Early-Stage Lung Cancer Diagnostics Market: Overview

The global early-stage lung cancer diagnostics market is expected to show significant growth over the forecast period, due to the rise in funding by governments for the development of novel drugs. According to GLOBOCAN, cancer burden has risen to 18.1 million cases and 9.6 million cancer deaths in 2017. GLOBOCAN also estimated that there have been 1.3 million cases of prostate cancer, worldwide, in 2017.

By drug type, the polyketides segment is expected to gain the maximum market share, though polyketides will be the most preferred drug for apoptosis-inducing. The prostate cancer segment, by application, is expected to dominate the market by revenue, due to the high adoption of early-stage lung cancer diagnostics for the treatment of prostate cancer.

Among all the distribution channels, the hospital pharmacies segment is expected to be the most dominant segment, whereas, the retail pharmacies segment is anticipated show a higher growth rate.

Early-Stage Lung Cancer Diagnostics Market: Regional Outlook

On the basis of geography, the early-stage lung cancer diagnostics market is classified into eight key regions, viz. North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and the Middle East and Africa. North America is expected to dominate the global early-stage lung cancer diagnostics market, due to the rise in research and development for the development of novel drugs.

Europe closely follows North America, due to the rising incidences of cancer in the region. The early-stage lung cancer diagnostics markets in APEJ and Japan are growing swiftly, owing to the rising number of contract research organizations in these regions. Latin America and the Middle East and Africa are the least lucrative regions for the early-stage lung cancer diagnostics market, due to the lack of awareness about the advanced therapies for the treatment of cancer among the people.

Early-Stage Lung Cancer Diagnostics Market: Key Players

Some of the key players found across the value chain of the early-stage lung cancer diagnostics market are BriaCell Therapeutics, Gilead Sciences, Inc., Cellectis S.A., Neon Therapeutics, Loxo Oncology, Bristol Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, Pfizer Inc., and AstraZeneca plc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Nordic Countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, Rest of MEA)

Report highlights:

• Detailed overview of the parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Early-Stage Lung Cancer Diagnostics Market: Segmentation

Tentatively, the global early-stage lung cancer diagnostics market can be segmented on the basis of drug type, application, distribution channel, and geography.

Based on drug type, the global early-stage lung cancer diagnostics market is segmented as:

• Polyketides
• Deferoxamine Mesylate
• Heavy Metal Antagonists
• Threonine Protein Phosphatases
• Others

Based on application, the early-stage lung cancer diagnostics market is segmented as:

• Prostate Cancer
• Brain Cancer
• Breast Cancer
• Leukemia
• Others

Based on distribution channel, the early-stage lung cancer diagnostics market is segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores